Skip to main content
OpenTrials
Completed

NCT Number: NCT02175940

VEGF and PEDF in Patients With Myopic Choroidal Neovascularization

This was a prospective, case-control study investigating aqueous levels of VEGF and PEDF in eyes with mCNV treated with IVB.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Myopic Choroidal Neovascularization PEDF Aqueous Level VEGF Aqueous Level

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Medical Retina Department, University of Molise

Cambpobasso, CB, 86100, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • pathologic myopia, defined as spherical equivalent >6 diopters and axial length >26 mm
  • posterior pole myopic retinal changes (posterior staphyloma, chorioretinal atrophy, papillary crescent);
  • fluorescein angiography, indocyanine green angiography and optical coherence tomography detection of the subfoveal or juxtafoveal choroidal neovascularization
  • clear ocular media;

Exclusion criteria

  • previous treatment for choroidal neovascularization, including the previous intravitreal drug injection or PDT
  • presence of other maculopathy as diabetic retinopathy or retinal vascular occlusion
  • history of recent myocardial infarction or other thromboembolic events
  • ongoing uncontrolled hypertension or glaucoma
  • refractive media opacities
  • previous eye surgery

Treatment and study plan

Primary outcomes

  1. vascular endothelial growth factor (VEGF) aqueous levels

    Time frame: 2 months

    VEGF aqueous levels before and after intravitreal ranibizumab

  2. pigment epithelium-derived factor (PEDF) aqueous levels

    Time frame: 2 months

    PEDF aqueous levels before and after intravitreal ranibizumab

Secondary outcomes

  1. best-corrected visual acuity

    Time frame: 2 months

  2. central retinal thickness

    Time frame: 2 months

Sponsors and collaborators

Lead sponsor

Università degli Studi di Brescia

Other

Collaborators

  • Antonio Porcellini
  • Ciro Costagliola
  • Fabiana Aceto
  • Francesco Semeraro
  • Mario R Romano
  • Roberto dell'Omo
  • Rodolfo Mastropasqua

Registry information

Official study title

Effect of Intravitreal Ranibizumab Injection on Aqueous Humor Concentrations of Vascular Endothelial Growth Factor and Pigment Epithelium-derived Factor in Patients With Myopic Choroidal Neovascularization.

Important dates

Study start
2013
Primary completion
2014
Study completion
2014
First posted
Jun 26, 2014
Registry last updated
Jun 26, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.